News about "Financial Results"

Zydus Reports Robust Growth in Q3 FY25 with a 17 Percent Increase in Revenue

Zydus Lifesciences recorded revenue from operations at INR 52,691 million, marking a 17 percent increase year-over-year.

Financial Results | 06/02/2025 | By Aishwarya

Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25

The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.

Financial Results | 31/01/2025 | By Aishwarya |  102

Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25

Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.

Financial Results | 05/11/2024 | By Aishwarya |  149

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

Financial Results | 29/10/2024 | By Aishwarya |  171

Strides Pharma Shows Strong Q1FY25 Results with 16.7 Percent of Revenue Growth

Strides Pharma Science Ltd. has announced its consolidated financial results for the quarter (Q1FY25).

Financial Results | 29/07/2024 | By Aishwarya |  140

Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance

Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.

Financial Results | 23/05/2024 | By Aishwarya |  181

Strides Announces Best-Ever Financial Results for FY24

Strides Pharma Science Ltd. has published its consolidated financial results for the quarter (Q4FY24) and full year (FY24) ended March 31, 2024.

Financial Results | 23/05/2024 | By Aishwarya |  511

Granules India Records 2 Percent Growth in Revenue from Operations in Q4FY24

Granules India Ltd., has announced its financial results for the quarter and financial year ended March 31, 2024.

Financial Results | 17/05/2024 | By Aishwarya |  197

Hikal Limited Shows Resilient Performance Amid Industry Headwinds

Hikal’s Panolisite undergone US FDA audit which was concluded with ‘Zero’ 483 observations. US FDA approval is in line with de-risking strategy for additional API site to service our global customer base.

Financial Results | 10/08/2023 | By Manvi |  393

Granules India Q1FY24 Revenue from Operations at INR 9855 mn down 3 Percent YoY

ROCE stood at 9.4 percent and net debt stood at INR 8,569 mn

Financial Results | 10/08/2023 | By Manvi |  312